United Therapeutics (UTHR) Free Cash Flow Growth (3y) (2012 - 2026)
United Therapeutics (UTHR) Free Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 39.19% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 31.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.68% |
| Dec 31, 2025 | 65.46% |
| Sep 30, 2025 | 0.65% |
| Jun 30, 2025 | 22.13% |
| Mar 31, 2025 | 11.97% |
| Dec 31, 2024 | 34.76% |
| Sep 30, 2024 | 29.43% |
| Jun 30, 2024 | 4.77% |
| Mar 31, 2024 | 60.91% |
| Dec 31, 2023 | 32.83% |
| Sep 30, 2023 | 12.69% |
| Jun 30, 2023 | -35.73% |
| Mar 31, 2023 | 20.92% |
| Dec 31, 2022 | 6.02% |
| Sep 30, 2022 | 28.29% |
| Jun 30, 2022 | -10.61% |
| Mar 31, 2022 | 34.29% |
| Dec 31, 2021 | -20.44% |
| Sep 30, 2021 | 4.28% |
| Jun 30, 2021 | -9.14% |